Study of new combo drug for advanced stomach cancer after first treatment fails
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. The drugs are designed to help your immune system fight the cancer while chemotherapy attacks it directly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has spread or cannot be completely removed (advanced stage).
- Your first treatment (which included a platinum drug and a type of chemotherapy) did not work or caused bad side effects.
- You have at least one tumor that can be measured on a scan.
- Your blood counts and liver/kidney function are within a certain range.
- You have not received a specific type of prior treatment called PD-1/CTLA-4 bispecific antibody or a chemotherapy called taxane for your first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and targeted radiation for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this approach helps shrink tumors or slow the disease.
This study tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or GEJ cancer that continued to grow after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.